SNW1 is a prognostic biomarker in prostate cancer-Reference-Cited by-同舟云学术

SNW1 is a prognostic biomarker in prostate cancer

Published:2019-05-01 Issue:1 Volume:14 Page:
ISSN:1746-1596
Container-title:Diagnostic Pathology
language:en
Short-container-title:Diagn Pathol

Author:

Höflmayer Doris,Willich Carla,Hube-Magg Claudia,Simon Ronald^ORCID,Lang Dagmar,Neubauer Emily,Jacobsen Frank,Hinsch Andrea,Luebke Andreas M.,Tsourlakis Marie Christina,Huland Hartwig,Graefen Markus,Haese Alexander,Heinzer Hans,Minner Sarah,Büscheck Franziska,Sauter Guido,Schlomm Thorsten,Steurer Stefan,Clauditz Till S.,Burandt Eike,Wilczak Waldemar,Bernreuther Christian

Funder

Bundesministerium für Bildung und Forschung

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13000-019-0810-8.pdf

Reference31 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

2. Leong GM, Subramaniam N, Figueroa J, Flanagan JL, Hayman MJ, Eisman JA, Kouzmenko AP. Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta-dependent transcription. J Biol Chem. 2001;276(21):18243–8.

3. Xu W, Angelis K, Danielpour D, Haddad MM, Bischof O, Campisi J, Stavnezer E, Medrano EE. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor. Proc Natl Acad Sci U S A. 2000;97(11):5924–9.